MCKESSON PHARMAC 55513071001 PROLIA, SYR 60MG/ML 1M

Out of stock

14 People watching this product now!

Payment Methods:

Prolia® (denosumab) is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy
Prolia is indicated as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer
Prolia is indicated as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer
All patients should receive calcium 1000 mg daily and at least 400 IU vitamin D daily
Pre-existing hypocalcemia must be corrected prior to initiating Prolia®
Administer 60 mg every 6 months as a subcutaneous injection in the upper arm, upper thigh, or abdomen
Each 1 mL single-use prefilled syringe of Prolia contains 60 mg denosumab (60 mg/mL solution), 4.7% sorbitol, 17 mM acetate, 0.01% polysorbate 20, Water for Injection (USP), and sodium hydroxide to a pH of 5.2
Store Prolia in a refrigerator at 2°C to 8°C (36°F to 46°F) in the original carton
Protect Prolia from direct light and heat